The stock's rise snapped a four-day losing streak.

DCF analysis, a reliable and data-driven approach to estimating its intrinsic value. Instead of using future free cash flow ...

Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced ...

Czech National Bank increased its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $175.17 which represents a decrease of $-3.33 or -1.87% from the prior close of $178.5. The stock opened at $176.86 and touched a low of ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

REGENXBIO to receive $110 million upfront, potential milestone payments of up to $700 million and meaningful double- ...

AbbVie's strong financials and potential for cash flow make it a valuable investment, despite risks from patent expirations.

Simcere Pharmaceutical said on Monday its unit had granted U.S. drugmaker AbbVie the option to license its new blood cancer ...